|
Federal
Register Notices > Notices
of Registration - 2001 > Cerilliant
Corporation
[Federal Register: June 25, 2001 (Volume 66,
Number 122)]
[Notices]
[Page 33714]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr25jn01-95]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice
of Registration
By Notice dated January 25, 2001, and published in
the Federal Register on February 14, 2001, (66 FR 10320), Cerilliant
Corporation, 14050 Summit Drive #121, P.O. Box 201088, Austin, Texas
78708-0189, made application to the Drug Enforcement Administration
(DEA) to be registered as a bulk manufacturer of the basic classes of
controlled substances listed below:
|
Drug |
Schedule |
| Cathinone (1235) |
I |
| Methcathinone (1237) |
I |
| N-Ethylamphetamine (1475) |
I |
| N, N-Dimethylamphetamine (1480) |
I |
| Aminorex (1585) |
I |
| 4-Methylaminorex (cis isomer)
(1590) |
I |
| Gamma hydroxybutyric acid
(2010) |
I |
| Methaqualone (2565) |
I |
| Alpha-Ethyltryptamine (7249) |
I |
| Lysergic acid diethylamide
(7315) |
I |
| Tetrahydrocannabinols (7370) |
I |
| Mescaline (7381) |
I |
| 3,4,5-Trimethoxyamphetamine |
I |
| 4-Bromo-2,
5-dimethoxyamphetamine (7390) |
I |
| 4-Bromo-2,
5-dimethoxyphenethylamine (7392) |
I |
| 4-Methyl-2,
5-dimethoxyamphetamine (7395) |
I |
| 2, 5-Dimethoxyamphetamine
(7396) |
I |
| 2,
5-Dimethoxy-4-ethylamphetamine (7399) |
I |
| 3, 4-Methylenedioxyamphetamine (7400) |
I |
| 5-Methoxy-3,
4-methylenedioxyamphetamine (7401) |
I |
| N-Hydroxy-3,
4-methylenedioxyamphetamine (7402) |
I |
| 3,
4-Methylenedioxy-N-ethylamphetamine (7404) |
I |
| 3,
4-Methylenedioxymethamphetamine (7405) |
I |
| 4-Methoxyamphetamine (7411) |
I |
| Bufotenine (7433) |
I |
| Diethyltryptamine (7434) |
I |
| Dimethyltryptamine (7435) |
I |
| Psilocybin (7437) |
I |
| Psilocyn (7438) |
I |
| Acetyldihydrocodeine (9051) |
I |
| Benzylmorphine (9052) |
I |
| Codeine-N-oxide (9053) |
I |
| Dihydromorphine (9145) |
I |
| Heroin (9200) |
I |
| Morphine-N-oxide (9307) |
I |
| Normorphine (9313) |
I |
| Pholcodine (9314) |
I |
| Acetylmethadol (9601) |
I |
| Allyprodine (9602) |
I |
| Alphacetylmethadol except Levo-Alphacetylmethadol (9603) |
I |
| Alphameprodine (9604) |
I |
| Alphamethadol (9605) |
I |
| Betacetylmethadol (9607) |
I |
| Betameprodine (9608) |
I |
| Betamethadol (9609) |
I |
| Betaprodine (9611) |
I |
| Hydromorphinol (9627) |
I |
| Noracymethadol (9633) |
I |
| Norlevorphanol (9634) |
I |
| Normethadone (9635) |
I |
| Trimeperidine (9646) |
I |
| Para-Fluorofentanyl (9812) |
I |
| 3-Methylfentanyl (9813) |
I |
| Alpha-methylfentanyl (9814) |
I |
| Acetyl-alpha-methylfentanyl
(9815) |
I |
| Beta-hydroxyfentanyl (9830) |
I |
| Beta-hydroxy-3-methylfentanyl
(9831) |
I |
| Alpha-Methylthiofentanyl (9832) |
I |
| 3-Methylthiofentanyl (9833) |
I |
| Thiofentanyl (9835) |
I |
| Amphetamine (1100) |
II |
| Methamphetamine (1105) |
II |
| Phenmetrazine (1631) |
II |
| Methylphenidate (1724) |
II |
| Amobarbital (2125) |
II |
| Pentobarbital (2270) |
II |
| Secobarbital (2315) |
II |
| Glutethimide (2550) |
II |
| Nabilone (7379) |
II |
| 1-Phenylcyclohexylamine (7460) |
II |
| Phencyclidine (7471) |
II |
| 1-Piperidinocyclohexanecarbonitrile (8603) |
II |
| Alphaprodine (9010) |
II |
| Cocaine (9041) |
II |
| Codeine (9050) |
II |
| Dihydrocodeine (9120) |
II |
| Oxycodone (9143) |
II |
| Hydromorphone (9150) |
II |
| Diphenoxylate (9170) |
II |
| Benzoylecgonine (9180) |
II |
| Ethylmorphine (9190) |
II |
| Hydrocodone (9193) |
II |
| Levomethorphan (9210) |
II |
| Levorphanol (9220) |
II |
| Isomethadone (9226) |
II |
| Meperidine (9230) |
II |
| Methadone (9250) |
II |
| Methadone-intermediate (9254) |
II |
| Morphine (9300) |
II |
| Thebaine (9333) |
II |
| Levo-alphacetylmethadol (9648) |
II |
| Oxymorphone (9652) |
II |
| Noroxymorphone (9668) |
II |
| Alfentanil (9737) |
II |
| Sufentanil (9740) |
II |
| Fentanyl (9801) |
II |
The firm plans to manufacture small quantities of
the listed controlled substances to make deuterated and non-deuterated
drug reference standards which will be distributed to analytical and
forensic laboratories for drug testing programs.
No comments or objections have been received.
DEA has considered the factors in Title
21, United States Code, Section 823(a) and determined that the
registration of Cerilliant Corporation to manufacture the listed
controlled substances is consistent with the public interest at this
time. DEA has investigated Cerilliant Corporation to ensure that the
company's registration is consistent with the public interest. This
investigation included inspection and testing of the company's physical
security systems, verification of the company's compliance with state
and local laws, and a review of the company's background and history.
Therefore, pursuant to 21
U.S.C. Sec. 823 and 28 CFR Secs. 0.100 and 0.104, the Deputy
Assistant Administrator, Office of Diversion Control, hereby orders that
the application submitted by the above firm for registration as a bulk
manufacturer of the basic classes of controlled substances listed above
is granted.
Dated: June 4, 2001.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 01-15835 Filed 6-22-01; 8:45 am]
BILLING CODE 4410-09-M
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
Back to
Top
Registration
Support
Toll Free Number: 1-800-882-9539
ARCOS
| Career Opportunities | Chemical Program |
Controlled
Substance Schedules | Drugs and
Chemicals of Concern
Electronic Commerce Initiatives | | Federal Register
Notices | Import Export | Links
| Meetings
and Events | NFLIS
Offices &
Directories | On-Line Forms & Applications |
Program
Description | Publications
|
Questions & Answers | Quotas
Reports Required by 21 CFR | Title 21 Regulations & Codified
CSA
Contact Us | Home
| Hot
Items | Site Map | Search | What's New
|
